Oncogenex Pharmaceuticals Inc. reported that a combination of its lead anticancer candidate apatorsen and the chemotherapy docetaxel met the primary endpoint of overall survival in the investigator-sponsored phase II Borealis-2 trial, reducing the risk of death for metastatic bladder cancer patients who failed initial therapy by 20 percent vs. treatment with docetaxel alone (hazard ratio (HR) of 0.80, 95 percent confidence interval: 0.65-0.98; p = 0.078).